Farxiga data 'have the potential to transform the standard of care'

1 September 2020

AstraZeneca’s (LSE: AZN) Farxiga (dapagliflozin) – on top of standard care – met a Phase III trial’s primary endpoint and reduced the composite of worsening renal function or risk of death in patients with chronic kidney disease (CKD) with or without type-2 diabetes (T2D).

The full results reported a 39% reduction in worsening of renal function or risk of cardiovascular or renal death, and highlight Farxiga as the first medicine to significantly prolong survival by 31% in this patient population.

Trial investigators from the DAPA-CKD study have said that the data have the potential to transform the standard of care for this patient population, which has a significant unmet need for new and improved treatment options.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK